Table 3. Univariate and multivariate analysis of variables affecting overall survival in 70 mCRPC patients.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age, years (continuous) | 0.97 (0.93∼1.02) | 0.25 | - | - |
| PSA, ng/ml (continuous) | 1.00 (1.00∼1.00) | 0.08 | - | - |
| LDH, U/l (continuous) | 1.00 (1.00∼1.00) | 0.07 | - | - |
| Gleason score of primary lesion (≤8 vs >8) | 1.09 (0.79-1.51) | 0.58 | - | - |
| Hemoglobin, g/l (continuous) | 0.97 (0.95∼0.99) | <0.01 | 1.00 (0.97∼1.02) | 0.69 |
| ALP, U/l (continuous) | 1.00 (1.00∼1.00) | <0.01 | 1.00 (1.00∼1.00) | 0.08 |
| ALB, g/l (continuous) | 0.85 (0.79∼0.91) | <0.01 | 0.91 (0.83∼0.99) | 0.04 |
| ECOG performance status (0-1 vs ≥2) | 5.50 (2.20-13.76) | <0.01 | 7.93 (2.35∼26.78) | <0.01 |
| Chemotherapy (No vs Yes) | 0.44 (0.22-0.89) | 0.02 | 0.54 (0.21∼1.39) | 0.20 |
| CTC enumeration (<5 vs ≥5) | 2.44 (1.23-4.84) | 0.01 | 2.73 (1.21∼6.13) | 0.02 |
| Stem cell gene expression (negative vs positive) | 2.43 (1.21-4.87) | 0.01 | 3.18 (1.32∼7.65) | 0.01 |
| EMT gene expression (negative vs positive) | 1.10 (0.56-2.15) | 0.79 | ||
PSA, prostate specific antigen; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; ALB, albumin; ECOG, Eastern Cooperative Oncology Group; CTC, circulating tumor cell; EMT, epithelial mesenchymal transition.